Darling Ingredients Inc. (DAR) stands at a crossroads, having transformed from a steady regional player in animal rendering and by-products into a global leader in sustainable ingredients and biofuels over the past decade. However, the company’s trajectory underscores the perils of commodity cyclicality and aggressive expansion, with revenue peaking at $6.79 billion in 2023 before contracting 16% to $5.72 billion in 2024—a stark reminder of vulnerability to raw material prices and biofuel margins. Stock prices mirrored this volatility, surging from yearly lows around $10 in 2020 to highs near $88 in 2022 amid the renewable diesel boom, only to retreat to lows of $33 in 2024. With the most recent close hovering around current levels, analysts’ price targets suggest a modest upside potential of about 21% to the mean, though the low end implies a 12% downside risk—highlighting the need for prudence in a sector prone to oversupply and policy shifts.
Revenue Growth and Operational Scale
Revenue expansion was the hallmark of DAR’s ascent, climbing cumulatively 95% from $3.39 billion in 2016 to $6.53 billion in 2022, driven by strategic acquisitions and the 2022 full consolidation of its Diamond Green Diesel (DGD) joint venture with Valero Energy. This biofuel arm capitalized on U.S. renewable diesel demand, fueled by low-carbon fuel standards in California and federal incentives under the Inflation Reduction Act. Employee headcount swelled 58% from 10,000 to 15,800 by 2023, boosting revenue per employee from $339,000 to a peak of $479,000 in 2021 before easing. Yet, 2024’s 16% revenue drop correlates tightly with softer animal protein by-products and renewable diesel cracks, exposing overreliance on volatile commodities. Looking ahead, analysts forecast a rebound to $6.46 billion in 2026 (13% growth from 2024) and $6.60 billion in 2027, predicated on capacity expansions at DGD and sustainable aviation fuel (SAF) ramp-ups—though execution risks loom if oil prices stabilize or subsidies wane.
Gross margins offer a cautious lens on efficiency, holding steady around 22-26% historically but dipping to 22.4% in 2024 from 24.2% in 2023. This metric is crucial as it strips out fixed costs, revealing core pricing power in rendering (fats, proteins) and biofuels. The slight projected uptick to 24.0% in 2025 signals stabilizing input costs, but I’ve seen similar recoveries fizzle in cyclical downturns.
Profitability and Earnings Trajectory
Earnings tell a more sobering story of peak-and-trough dynamics. Net income rocketed 534% from $107 million in 2016 to $747 million in 2022, with earnings per share (EPS) multiplying from $0.62 to $4.58—a direct reflection of biofuel tailwinds post-2020. EBT margins peaked at 17.3% in 2021, underscoring operational leverage, but cratered to just 0.99% in 2025 estimates amid high feedstock costs and DGD maintenance turnarounds. ROE, a key gauge of shareholder returns, followed suit: 20.7% in 2022 down to 6.1% in 2024 (70% decline), signaling eroding capital efficiency.
Free cash flow per share (FCF/sh), vital for debt servicing and dividends, peaked at $5.63 in 2023 before 2024’s $3.31 reflected capex moderation. Total FCF swung from $155 million in 2016 to a robust $529 million in 2024 (242% increase), buoyed by operating cash flow climbing to $839 million despite capex at $311 million (down 43% from 2023’s $545 million). Analyst projections eye FCF/sh at $7.87 in 2026, implying dividend sustainability and buyback potential, but only if margins hold. Stock price appreciation through 2022 (from ~$21 revenue/sh to $41) tracked EPS growth closely, with PE ratios compressing from 32x in 2020 to 13x by 2022—attractive for value hunters—yet expanding to 53x on 2025’s depressed earnings.
Balance Sheet Strength Amid Debt Pressures
DAR’s balance sheet reveals the double-edged sword of growth. Shareholders’ equity ballooned 115% from $2.08 billion in 2016 to $4.46 billion in 2024, with book value per share (BV/sh) up 122% to $28. Working capital surged 90% to $396 million in 2024, providing liquidity buffers. However, total debt exploded 166% from $1.51 billion in 2020 to $4.42 billion in 2023 post-DGD buyout, pushing net debt to $3.93 billion by 2024 (down slightly from 2023’s peak). This leverage spike correlates with 2022’s revenue jump but amplified 2024’s downturn, with ROIC falling to 3.5% from 11.7% in 2021.
Debt metrics warrant vigilance: EV/Sales at 1.63x in 2024 (up from 0.94x trough) and EV/FCF at 17.6x remain reasonable versus peaks above 49x, but rising interest rates could pinch. Net debt to 2025’s projected equity implies ongoing deleveraging if FCF forecasts materialize, dropping to manageable levels around $511 million. PB ratios, contracting from 3.4x in 2021 to 1.2x now, suggest the stock trades near tangible value—comforting for balance-sheet focused investors, yet vulnerable if asset writedowns hit rendering plants.
Valuation in Context of Market Cycles
Valuation multiples paint DAR as undervalued relative to its 2021-22 glory but stretched on near-term earnings. PS ratios eased from 2.6x in 2020 to 0.94x in 2024, aligning with revenue normalization, while historical PE averages ~20x versus 19x currently. Compared to peers in waste-to-value (e.g., Tyson spin-offs or biofuel plays), DAR’s 1.2x PB is compelling if ROE rebounds to 12.5% as 2026 estimates suggest. Stock lows/highs tell the tale: 2022’s $56-$88 range captured peak euphoria, but 2024’s $33-$51 reflects margin compression, with the recent close positioned midway—offering ~37% upside to high targets but exposed to low-end cuts if biofuel hype fades.
Insider Activity and Sentiment Signals
Insider transactions lean bearish, with zero buys across 2025-early 2026 and total sells valued at millions, including the Chairman/CEO offloading over 100,000 shares in May and August 2025 (reducing holdings significantly), plus an EVP/General Counsel sale. While routine (e.g., option exercises), the absence of purchases amid a 40%+ stock drawdown from 2022 highs signals caution from those closest to operations. No buys in 12 months correlates with profitability troughs, often a red flag for near-term catalysts.
Future Outlook and Key Risks
Analysts envision recovery: Revenue/sh to $41 by 2027 (16% from 2024), EPS to $3.66 in 2027 (109% from 2024’s $1.75), with capex stabilizing around $410 million. This hinges on DGD’s Phase 3 expansions (adding 500 million gallons/year by 2027) and SAF demand under Biden-era mandates, potentially lifting EBT to $805 million in 2026. Shares outstanding dip slightly to 158 million, aiding per-share metrics.
Yet, as a pragmatist, I emphasize downsides. Commodity gluts (e.g., used cooking oil oversupply) crushed 2024 margins, echoing 2015-16 troughs pre-boom. Geopolitical risks—Ukraine war inflating feedstocks—and election-year policy flux could derail subsidies. Debt at $4+ billion leaves little room for error; a sustained ROA below 3% (versus 11% peak) erodes confidence. Stock correlation to revenue (r~0.85 historically) implies flat-to-downside if growth falters.
In sum, DAR offers steady-performer potential for patient holders, with analyst means implying 20%+ total returns if biofuels deliver. But with insider selling, leverage, and cyclical headwinds, I’d allocate modestly—prioritizing FCF coverage and margin inflection before scaling up. Monitor Q1 2026 earnings for DGD volumes; any miss could validate the low target downside.
(Word count: 1,128)